EUVIMEDEUVIMED entdecken
Open Access

The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis

Georgene E Hergenroeder, Anna Faino, Gracia Bridges, Lauren E Bartlett, Jonathan D Cogen, Nicole Green, Sharon McNamara, David P Nichols, Kathleen J Ramos

Journal of Cystic Fibrosis · 2023

DOI: 10.1016/j.jcf.2023.08.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2023. Verfasst von Georgene E Hergenroeder und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Sleep Medicine, Seattle Children's Hospital; Department of Pediatrics, University of Washington. Electronic address: hergen…. Hauptthemen laut MEDLINE: Vitamin A, Cystic Fibrosis. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Cystic Fibrosis Foundation, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: While elexacaftor/tezacaftor/ivacaftor (ETI) has improved the pulmonary health of many people with cystic fibrosis (PwCF), less is known about ETI effectiveness for extra-pulmonary manifestations, including fat-soluble vitamin malabsorption. This study aims to evaluate ETI's impact on vitamin A, D, E, and international normalized ratio (INR, an indirect marker for Vitamin K) serum levels. METHODS: Retrospective cohort study of PwCF ≥12 years receiving ETI. Vitamin levels up to four years preceding and up to two years following ETI initiation were collected. Pairwise comparisons of vitamin levels pre/post-ETI initiation were made using Wilcoxon signed rank and McNemar's tests. Linear mixed effect models were used to regress vitamin levels on time since starting ETI, ETI use (yes/no), the interaction between time and ETI use, and age. RESULTS: Two hundred and sixty-four participants met study inclusion, and 169 (64%) had post-ETI initiation vitamin levels. Median vitamin A levels increased from 422.0 to 471.0 mcg/L (p < 0.001), median vitamin D levels increased from 28.5 to 30.8 ng/mL (p = 0.003), and there were no significant changes in median vitamin E or INR. Vitamin A levels rose at a rate of 40.7 mcg/L/year (CI 11.3, 70.2) after ETI start. CONCLUSIONS: ETI initiation is associated with increased median vitamin A and vitamin D levels, but no change in median vitamin E or INR levels. Ongoing monitoring of vitamin levels after ETI initiation is needed to screen for potential deficiencies and toxicities, particularly in light of case reports of hypervitaminosis A following ETI initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vitamin ACystic FibrosisHumansRetrospective StudiesVitaminsVitamin DVitamin ECystic Fibrosis Transmembrane Conductance RegulatorAminophenolsBenzodioxolesMutationPyrazolesPyridinesPyrrolidinesQuinolonesIndoles

Stichwörter der Autor:innen

Cystic fibrosisETIElexacaftor/tezacaftor/ivacaftorHypervitaminosis APancreatic insufficiencyVitamin levels

Substanzen

Vitamin AVitaminsVitamin DVitamin ECystic Fibrosis Transmembrane Conductance RegulatorAminophenolsBenzodioxoleselexacaftorPyrazolesPyridines

Autor:innen und Institutionen

  • Division of Pulmonary and Sleep Medicine, Seattle Children's Hospital; Department of Pediatrics, University of Washington. Electronic address: hergenroeg@chop.edu.
  • Core for Biostatistics, Epidemiology, and Analytics in Research, Seattle Children's Research Institute.
  • Division of Pulmonary and Sleep Medicine, Seattle Children's Hospital.
  • Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington.
  • Division of Pulmonary and Sleep Medicine, Seattle Children's Hospital; Department of Pediatrics, University of Washington.
  • Department of Pediatrics, University of Washington; Division of Gastroenterology and Hepatology, Seattle Children's Hospital.

Förderung

  • NIDDK NIH HHS
  • Cystic Fibrosis Foundation
  • National Institutes of Health

Zitieren

APA

Hergenroeder, G. E., Faino, A., Bridges, G., Bartlett, L. E., Cogen, J. D., Green, N., McNamara, S., Nichols, D. P., & Ramos, K. J. (2023). The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2023.08.002

Vancouver

Hergenroeder GE, Faino A, Bridges G, Bartlett LE, Cogen JD, Green N, et al. The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis. Journal of Cystic Fibrosis. 2023. doi:10.1016/j.jcf.2023.08.002

BibTeX
@article{Hergenroeder2023,
  author = {Hergenroeder, Georgene E and Faino, Anna and Bridges, Gracia and Bartlett, Lauren E and Cogen, Jonathan D and Green, Nicole and McNamara, Sharon and Nichols, David P and Ramos, Kathleen J},
  title = {The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis},
  journal = {Journal of Cystic Fibrosis},
  year = {2023},
  doi = {10.1016/j.jcf.2023.08.002}
}
Kostenlos starten →